This study will examine the safety and efficacy of posaconazole in general use in Korea.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice|
|Study Start Date:||February 2012|
|Study Completion Date:||November 2013|
|Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
Drug: Posaconazole oral suspension 40 mg/mL
Posaconazole oral suspension prescribed according to the current local label
Other Name: NOXAFIL